MEN2312 for Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the trial involves a new drug, it's possible that some medications might need to be adjusted. Please consult with the trial coordinators for specific guidance.
Are You a Good Fit for This Trial?
This trial is for adults with advanced breast cancer. Specific details about eligibility criteria are not provided, but typically participants would need to have a certain stage of cancer and meet health requirements set by the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive MEN2312 as monotherapy or in combination with elacestrant
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- MEN2312
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stemline Therapeutics, Inc.
Lead Sponsor
Stemline Therapeutics, Inc.
Lead Sponsor